TCL Archive Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer July 31, 2009
TCL Archive Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint May 31, 2013
TCL Archive RTOG: Hormone Therapy Increases Survival When Combined With Radiation Therapy July 29, 2011